Navigation Links
Case Report Suggests Microbiome Therapeutics' NM504 May Improve Tolerability of Metformin While Improving Blood Glucose Control
Date:9/11/2013

sociated with type 2 diabetes.  Modern diets often lack essential ingredients that support a healthy microbiome, so we designed NM504 to replace key missing elements that impact the GI microbiome in ways known to be beneficial to metabolic and gastrointestinal health.  We look forward to completing our pilot trial that is further testing the hypothesis that NM504 may have utility as an adjunctive therapy to metformin."

MBT is developing evidence-based microbiome modulators—therapies designed to alter bacterial populations and their environment in the gastrointestinal (GI) tract to treat and prevent serious health conditions.  MBT's microbiome modulators act on multiple factors in the GI environment, providing specialized ingredients that augment the growth of targeted desirable bacterial strains and discourage the growth of others that may be harmful.  These shifts in the GI microbiome have the potential to have a major impact on factors affecting metabolism and weight, such as the endocrine response that affects appetite, metabolism and energy storage. 

NM504 contains a proprietary combination of plant-derived soluble and insoluble fibers and antioxidants formulated to help prediabetic and diabetic individuals achieve healthy blood glucose levels and manage their body weight.  NM504 is designed to shift the GI microbiome by replacing essential ingredients that are typically missing in the diets of prediabetic and diabetic individuals. This replacement strategy provides an advantage for beneficial members of the gut microbiota, while disadvantaging others that are harmful to metabolic health. The resulting microbiome shift produces an increase in the production of metabolites and signaling molecules that help regulate metabolic hormones, improve GI motility, maintain the protective intestinal mucosal barrier, reduce caloric absorption and reduce appetite. 

NM504 is being studied in two
'/>"/>

SOURCE MicroBiome Therapeutics LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. MarketPublishers.com Added New Report on L-(-)-Carnitine HCl (CAS 6645-46-1) Market to Its Catalogue
2. MarketPublishers.com Added New Report on 1,2 Hexanediol (CAS 6920-22-5) Market to Its Catalogue
3. New Reporting Guidelines For Case Reports Presented At The Congress On Peer Review And Biomedical Publication And Published In Seven Medical Journals
4. US Bioactive Wound Care Market 2016: Global Scenario, Trends, Industry Analysis, Size, Share And Forecast, 2012-2016, Report Available Online by Researchmoz.us
5. MarketPublishers.com Added New Report on Coconut Oil (CAS 8001-31-8) Market to Its Catalogue
6. MarketPublishers.com Added New Report on STRONTIUM ALUMINATE (CAS 12004-37-4) Market to Its Catalogue
7. MarketPublishers.com Added New Report on Hexamine (CAS 100-97-0) Market to Its Catalogue
8. Global Biopesticides Market 2012-2016: Worldwide Industry Latest Market Share, Strategy, Growth, Size, Trends and Forecast Research Report 2016
9. MarketPublishers.com Added New Report on HUMIC ACID (CAS 1415-93-6) Market to Its Catalogue
10. Legislative Benefits and Unmet Needs to Drive the Market for Orphan Drugs, According to a New Report by Global Industry Analysts, Inc.
11. MarketPublishers.com Added New Report on Anhydrous Hydrofluoric Acid (CAS 7664-39-3) Market to Its Catalogue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... May 21, 2015 Specialty Pharmacy ... and been admitted to BPA Worldwide as a ... will track audience data for Specialty Pharmacy Times ... , “By becoming a member of BPA Worldwide, ... providing our clients with the most reliable, unequaled ...
(Date:5/21/2015)... Calif. , May 21, 2015  The ... Orrin Hatch (R-UT) and Amy Klobuchar ... Extensions Now Accelerating Cures & Treatments, or OPEN ... rare disease patient advocacy organizations, this bipartisan legislation ... and affordable medicines to rare disease patients by ...
(Date:5/21/2015)... ANGELES , May 21, 2015  CytRx ... and development company specializing in oncology, today announced ... clinical trial with aldoxorubicin for the treatment of ... brain cancer.  The open-label, multisite trial is designed ... aldoxorubicin in patients whose tumors have progressed following ...
(Date:5/21/2015)... May 21, 2015 Veolia’s environmental ... exclusive North American distribution agreement with VWR to ... , With more than 160 years of experience, ... services for laboratory and production facilities, has cultivated ... and differentiated services to enable science. Endetec’s ...
Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
... At the Boston Atrial,Fibrillation Symposium, Stereotaxis, Inc. (Nasdaq: ... remote magnetic ablation that it believes will enhance ... Navigation,System. In booth #917, Stereotaxis will exhibit ... Cardiodrive(R) System for enhanced remote,catheter control and improved ...
... 14 In meetings held in association,with the JP ... (Nasdaq and MTA: CTIC) reviewed 2009 targeted milestones and ... approvals in 2009 in,addition to potential label expansion for ... Spectrum Pharmaceuticals, Inc.,(Spectrum) for Zevalin. , ...
... At the end of December,Trinitas Comprehensive Cancer Center ... state of New Jersey to offer cancer patients treatment ... VAR ).,RapidArc is a fast, precise form of ... is possible with conventional radiation therapy,technologies. By delivering ...
Cached Biology Technology:Stereotaxis Showcases Advancements for Remote Magnetic Ablations 2Stereotaxis Showcases Advancements for Remote Magnetic Ablations 3Stereotaxis Showcases Advancements for Remote Magnetic Ablations 4Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 2Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 3Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 4Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 5Cell Therapeutics Targeting Potential Zevalin Label Expansion, Pixantrone and OPAXIO Drug Approvals to Grow Commercial Operations and Revenues in 2009 6Trinitas Comprehensive Cancer Center Now Offering Cancer Patients Faster, Ultra-Precise Radiation Using New RapidArc Technology 2Trinitas Comprehensive Cancer Center Now Offering Cancer Patients Faster, Ultra-Precise Radiation Using New RapidArc Technology 3
(Date:5/22/2015)... According to a new market research report ... by Software (Middleware, Databases), by Hardware (Cameras, Integrated Devices), ... - Global Forecast to 2020", published by MarketsandMarkets, Facial ... to $6.19 Billion by 2020, at a CAGR of ... and   43 Figures spread through 140 Pages and ...
(Date:5/21/2015)... -- The Sync Project™ , a global collaboration ... announced a collaborative partnership with Berklee,s Institute for ... collaboration on original research, joint course development and an ... The Sync Project and BerkleeICE are exploring the launch ... 2015-2016 academic year.  The course will ...
(Date:5/20/2015)... Conn. , May 20, 2015 NXT-ID, ... announces that its wholly owned subsidiary, 3D-ID LLC, a ... under Team Battelle for the biometrics technology portion of ... Suite Contract from the Department of the Army. ... recognition products developed for government, law enforcement and security ...
Breaking Biology News(10 mins):Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... Presbycusis, or age-related hearing loss, accounts for 30 percent ... lose their hearing as they get older but other people ... answer may be in a study released online in the ... online at http://hmg.oxfordjournals.org/papbyrecent.dtl . "This ...
... find their way back to their birthplace to reproduce after ... scientists for more than a century. But marine biologists at ... might finally have unraveled the secret. At the beginning ... magnetic field of their home area and "imprint" on it, ...
... meaning of a rare mineral that can be used to track ... others better understand what we,re probably in for over the next ... heat and, ultimately, to change life as we know it. ... in the next hundred years or so, and that many species ...
Cached Biology News:House Ear Institute, TGen and Belgian researchers identify gene in age-related hearing loss 2No place like home: New theory for how salmon, sea turtles find their birthplace 2No place like home: New theory for how salmon, sea turtles find their birthplace 3Foretelling a major meltdown 2Foretelling a major meltdown 3
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... centrifuge offers both high-speed and high-volume ... of rotor options, making it ideal for ... Maximum Versatility , High-speed (up to ... or high-volume (4 x 250mL) swinging bucket ...
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
...
Biology Products: